EHR-based annual PSA reminder and shared decision-making program across a 10-hospital system
Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health System
This trial will test whether an annual electronic health record reminder that prompts shared decision-making and guideline-based referral improves PSA screening and appropriate follow-up for men at average or high risk in a large health system.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40000 (estimated) |
| Ages | 40 Years to 75 Years |
| Sex | Male |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Trial ID | NCT07109427 on ClinicalTrials.gov |
What this trial studies
The program adds an annual PSA health maintenance reminder to the electronic health record with defined referral thresholds aligned to NCCN risk stratification and enhanced clinical decision support to guide clinicians. It targets men receiving primary care within a 10-hospital integrated system and uses system-level tools to reduce provider variation in screening and referral practices. The intervention emphasizes shared decision-making at the point of care and standardized referral triggers intended to prioritize clinically significant disease while limiting overdiagnosis. Outcomes include screening rates, guideline-concordant referrals, and downstream presentation stage.
Who should consider this trial
Good fit: Men who receive primary care within the BJC Health System, have had at least one primary care visit in the screening year, are age 50–75 (or age 40–75 if African American or otherwise high risk), and do not have a history of prostate cancer are ideal candidates.
Not a fit: People outside the BJC Health System, women, men with a prior prostate cancer diagnosis, or men outside the specified age/risk ranges are unlikely to benefit from this intervention.
Why it matters
Potential benefit: If successful, the intervention could increase guideline-concordant PSA screening and timely referral, reducing late-stage prostate cancer presentations without markedly increasing overdiagnosis.
How similar studies have performed: Previous work shows that EHR alerts and decision-support tools can increase guideline-concordant screening and shared decision-making, though effects on reducing late-stage cancer diagnosis are less consistently proven.
Eligibility criteria
Show full inclusion / exclusion criteria
Eligibility Criteria:
* Receive care within the BJC Health System
* Have had at least one primary care physician appointment in the calendar year of PSA screening (primary care)
* Be male
* Not have a history of prostate cancer
* Meet one of the following risk criteria:
* High Risk for Prostate Cancer
* African American, between the ages of 40 and 75 (inclusive), or
* Family history of prostate, breast, ovarian, and/or pancreatic cancer, or
* Known familial germline mutation OR
* Average Risk for Prostate Cancer
* Between the ages of 50 and 75 (inclusive)
Where this trial is running
St Louis, Missouri
- Washington University School of Medicine — St Louis, Missouri, United States (Recruiting)
Study contacts
- Principal investigator: Lannis Hall, M.D., MPH — Washington University School of Medicine
- Study coordinator: Lannis Hall, M.D., MPH
- Email: lannishall@wustl.edu
- Phone: 636-916-9947
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.